FGF-18 Polymeric Scaffold for Targeted Cartilage Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions delivering Fibroblast Growth Factor 18 (FGF-18) for treating cartilage disorders like osteoarthritis face challenges in selectively promoting cartilage growth only in damaged areas, leading to unwanted growth in healthy joints and instability of the protein due to chemical or physical instabilities.
Innovation Solution
A substance delivery system comprising a polymeric matrix, such as a collagen-based scaffold or membrane, incorporating FGF-18, which can slowly release the drug and include chondrogenic cells like mesenchymal stem cells or chondrocytes to promote targeted cartilage repair.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FGF-18 is injected intraarticularly to treat cartilage disorders, then cartilage growth is promoted in damaged areas, but uncontrolled cartilage growth occurs in healthy areas leading to reduced joint mobility
Solution Approach 1:
The patent applies local quality by incorporating FGF-18 directly into the scaffold material at the defect site, ensuring the growth factor is delivered only where needed rather than systemically throughout the joint. This localized delivery mechanism promotes cartilage regeneration specifically in damaged areas while avoiding unwanted growth in healthy regions.
Solution Approach 2:
The scaffold acts as an intermediary carrier that binds and releases FGF-18 in a controlled manner. This intermediary system allows for sustained local release of the growth factor at the defect site, preventing systemic distribution and associated side effects while maintaining therapeutic efficacy.
2Productivity
If FGF-18 is delivered systemically to ensure adequate dosage, then treatment effectiveness is improved, but protein stability decreases due to chemical or physical degradation
Solution Approach 1:
The scaffold serves as a protective intermediary that shields FGF-18 from chemical and physical degradation in the joint environment. By embedding the growth factor within the scaffold matrix, the system maintains protein stability while enabling controlled release at the target site, thus preserving both effectiveness and stability.
Solution Approach 2:
The patent utilizes parameter changes by controlling the release kinetics of FGF-18 from the scaffold through material composition and structural design. This controlled release mechanism maintains adequate therapeutic dosing over time while protecting the protein from degradation, balancing effectiveness and stability.
3Speed
If FGF-18 is released quickly from the scaffold to achieve rapid therapeutic effect, then treatment speed is improved, but duration of action is reduced requiring repeated treatments
Solution Approach 1:
The scaffold design incorporates parameter changes in its release kinetics, transitioning from an initial burst release phase to a sustained release phase. This dual-phase release profile enables both rapid initial therapeutic effect and prolonged action, reducing the need for repeated treatments while maintaining effective cartilage repair rates.
Solution Approach 2:
The scaffold ensures continuity of useful action by maintaining FGF-18 release over an extended period. The controlled release mechanism prevents premature depletion of the growth factor, providing continuous therapeutic effect that sustains cartilage regeneration throughout the healing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively delivers FGF-18 to damaged cartilage areas, enhancing cartilage repair quality and reducing unwanted growth in healthy joints by providing a stable and controlled release of the anabolic drug, improving integration and quality of hyaline cartilage production.
Implementation Method 1
it would be preferable if FGF-18 is slowly released from the scaffold/membrane to the surrounding tissue
Data Source
AI summary
The invention relates to the field of pharmaceutical compositions. More particularly it is directed to substance delivery system (or implant), such as scaffolds and membranes, comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects.